Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jenia Berelovich"'
Autor:
Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Yotam Bronstein, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Aaron Ronson, Uri Abadi, Levi Shvidel, Galia Stemer, Sigi Kay, Chen Glait Santar, Moran Barak, Noa Rivlin, Natalie Kaminsky, Raanan Cohen, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini
Publikováno v:
HemaSphere, Vol 7, p e4428024 (2023)
Externí odkaz:
https://doaj.org/article/12416f3e28da45aea43d694ae2636cac
Autor:
Galia Stemer, Ofir Wolach, Itai Levi, Boaz Nachmias, Sigal Tavor, Jonathan Canaani, Yishai Ofran, Chezi Ganzel, Tsila Zuckerman, Doaa Okasha, Ilana Hellmann, Tamar Tadmor, Najib Dally, Raanan Cohen, Jenia Berelovich, Keren Ofek, Noa Rivlin, Neta Frankel, Moshe Grunspan, Yakir Moshe
Publikováno v:
Blood. 140:6162-6164
Autor:
Chezi Ganzel, Yakir Moshe, Itai Levi, Boaz Nachmias, Sigal Tavor, Jonathan Canaani, Tsila Zuckerman, Doaa Okasha, Ilana Hellmann, Tamar Tadmor, Najib Dally, Galia Stemer, Raanan Cohen, Jenia Berelovich, Noa Rivlin, Neta Frankel, Moshe Grunspan, Keren Ofek, Yishai Ofran, Ofir Wolach
Publikováno v:
Blood. 140:9002-9004
Autor:
Jonathan Canaani, Neta Frankel, Ofir Wolach, David Lavie, Galia Stemer, Moshe Grunspan, Yishai Ofran, Sigal Tavor, Yakir Moshe, Keren Ofek, Jenia Berelovich, Tsila Zuckerman, Ilana Hellmann, Tamar Tadmor, Itai Levi
Publikováno v:
Blood. 138:1246-1246
Background: Venetoclax-based combinations were recently approved to treat patients (pts) with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Limited prospective 'real-world' data is available on treatment patterns of venetoclax-b
Autor:
Gilad Itchaki, Uri Abadi, Itai Levi, Lev Shvidel, Ohad Benjamini, Raanan Cohen, Neta Goldschmidt, Tamar Tadmor, Yair Herishanu, Riva Fineman, Andrei Braester, Rosa Ruchlemer, Jenia Berelovich, Keren Ofek, Najib Dally, Neta Frankel, Moshe Grunspan, Ariel Aviv
Publikováno v:
Blood. 138:3727-3727
Background: The BCL-2 inhibitor venetoclax in combination with an anti-CD20 monoclonal antibody (rituximab or obinutuzumab) has demonstrated superior outcomes and manageable safety as compared to chemo-immunotherapy in phase III clinical trials for c